Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776919 | 0.91 | DRD4 (0.56) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL5636691 | 0.87 | KCNA3 (0.46) | DRD4ALDH1A1DRD2DRD3L3MBTL1 | |
| SCHEMBL3446131 | 0.86 | DRD4 (0.53) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL2280839 | 0.86 | DRD4 (0.53) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL6557649 | 0.85 | MAOB (0.57) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL23893979 | 0.85 | LTA4H (0.54) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL4089033 | 0.85 | DRD4 (0.51) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL17445905 | 0.82 | ATM (0.60) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL18235025 | 0.82 | DRD4 (0.57) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL7759148 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1MAOBL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3836916-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 Therapeutics, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| CN-112839646-A | Benzothiophene estrogen receptor modulators for the treatment of medical disorders | G1治疗公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| WO-2020132004-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132004-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-6329523-B1 | FOR ANTIBACTERIAL PHARMACEUTICAL USE, USEFUL FOR IDENTIFYING METAL CHELATING SPECIES FOR ?HEAVY METAL? THERAPY; IMAGING AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6207826-B1 | Macrocyclic compounds having nitrogen-containing linkages | ISIS PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6197965-B1 | POLYARYLALKYLAMINO-SUBSTITUED PYRIDINE DERIVATIVES; DRUGS, MEDICINE, DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| EP-0817787-A4 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1998010286-A1 | METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998005961-A1 | COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996014283-A1 | PROCESS AND INTERMEDIATES FOR PREPARING TRIPHENYLTRIFLUOROPROPANES AND -PROPENES | EGIS Gyógyszergyár Rt. (HU) | 1996-05-17 | — | — | WO | disclosed |
| US-5235072-A | 2-OXABICYCLO(2,2,1)HEPTANE DERIVATIVES AND PHARMACEUTICAL | SCHERING AKTIENGSELLSCHAFT (DE) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | DRD4 3224/4885KDM4E 963/4885ALDH1A1 1156/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | DRD4 3109/4885KDM4E 80/4885ALDH1A1 4466/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | DRD4 3224/4885KDM4E 963/4885ALDH1A1 1156/4885 |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | CDK6, ESR1, CDK4 | DRD4 3164/4885KDM4E 543/4885ALDH1A1 1521/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | DRD4 1783/4885KDM4E 311/4885ALDH1A1 3913/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | DRD4 3224/4885KDM4E 963/4885ALDH1A1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.